Clinical Trial Update: The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's [Phase 2]

View source ↗

Summary

Phase 2 trial update on LeUprolide plus a cholinesterase inhibitor for Alzheimer's disease and mild cognitive impairment. The study (NCT03649724) is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Cholinesterase inhibitor
• Leuprolide (Leuprolide acetate)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Alzheimer Disease, Mild Cognitive Impairment | Phase 2 | Status: ACTIVE_NOT_RECRUITING